Representative Matters

  • Zeltiq Aesthetics (Nasdaq: ZLTQ) in its US$105 million initial public offering
  • Neothetics in its US$65 million initial public offering and its sale to Evofem Biosciences
  • Nexvet Biopharma (Nasdaq: NVET) in its US$40 million initial public offering
  • Sientra in its US$115 million follow‑on offering
  • Halozyme Therapeutics, Inc. in numerous follow‑on offerings
  • GenMark Diagnostics (Nasdaq: GNMK) in its initial public offering and numerous follow‑on offerings
  • Maxwell Technologies in its follow‑on offering and convertible note offering
  • DragonWave (Nasdaq: DRWI; TSX: DRI) in numerous follow‑on offerings
  • Cytori Therapeutics (Nasdaq: CYTX) in numerous follow‑on offerings and rights offering
  • Mast Therapeutics, Inc. in its sale to Savara and in numerous follow‑on offerings
  • QUALCOMM Incorporated in numerous acquisitions, venture financings and other strategic transactions
  • DTS in its US$1.0 billion sale to Tessera Technologies, as well as numerous acquisitions
  • NuVasive in its US$650 million 2.25% Convertible Senior Note offering and numerous acquisitions
  • P.F. Chang's China Bistro in its US$1.1 billion sale to Centerbridge Partners
  • The Active Network, Inc. in its US$1.05 billion sale to Vista Equity Partners
  • Life Technologies Corporation in various acquisitions, venture financings and other strategic transactions
  • Reva Medical (ASX: RVA) in its convertible note offerings
  • aTyr Pharma Inc. in its venture financings and other strategic transactions
  • Epic Sciences, Inc. in its venture financings and other strategic transactions